Great interest in the Initial Public Offering of Q-Med

Great interest in the Initial Public Offering of Q-Med Offer price set at SEK 58 per share Q-Med's initial public offering has generated substantial interest in the investment community. The global offering of shares was subscribed nearly five times. The offer price has been set at SEK 58 per share (the offer price range was SEK 50 - 58 per share). The net proceeds to the company from this issuance of 5,000,000 shares will amount to approximately SEK 260 million. In addition, the Managers have been granted an option to purchase up to an additional 1,000,000 shares to cover over-allotments. A large number of Swedish and international institutional investors have shown a significant interest in the Global Offering. Within Sweden, approximately 9,000 people have applied to subscribe for shares in the Global Offering. Settlement for the shares will occur on December 3, 1999. The shares are expected to be listed on the O-list of the Stockholm Stock Exchange on December 6, 1999. Fleming Aros is acting as Lead Manager and bookrunner in connection with the initial public offering. For enquiries, please contact Per Olof Wallström, President and Chief Executive Officer, Tel: +46-18-474 90 00 or +46-70-974 90 70. Q-Med AB (publ), Seminariegatan 21, 752 28 Uppsala, Sweden Telephone: +46-18-474 90 00. Fax: +46-18-474 90 01. Org. nr. 556258-6882. ------------------------------------------------------------ Please visit for further information The following files are available for download:

About Us

Q-Med is a rapidly growing and profitable biotechnology and medical device company that develops, produces and markets medical implants. Operations focus on four areas, Esthetics, Orthopedics, Uro-Gynecology, and Cell Therapy and Encapsulation.